Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Amanda Brock

Nurse Practitioner, Primary Care Blountstown, FL Nurse Practitioner

NPI 1063121689 CMS profile 11417208

17808 Ne Charlie Johns St, Blountstown, FL 32424

Open in the dashboard

General payments

$2,583

125 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Brock of Blountstown, FL is reported in the CMS Open Payments database as having received $2,583 across 125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,024 36
2024 General $1,039 54
2023 General $520 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Brock
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Amanda Brock were reported at $1,024. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Amanda Brock Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $0 $139 $44–$421 $149
2023 $520 $163 $53–$481 $160
2024 $1,039 $176 $54–$511 $164
2025 $1,024 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $450 19 payments
  2. Lilly USA, LLC $429 32 payments
  3. AbbVie, Inc. $361 14 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $233 9 payments
  5. Edwards Lifesciences Corporation $167 1 payment
  6. Pfizer Inc. $146 8 payments
  7. Dexcom, Inc. $139 5 payments
  8. Amgen Inc. $130 8 payments
  9. Novo Nordisk Inc $88 5 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $76 4 payments
  11. Other $364 20 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,583 125 payments
Products named General payments · program years 2023–2025
  1. AIRSUPRA $292 11 payments
  2. QULIPTA $283 9 payments
  3. FARXIGA $268 9 payments
  4. JARDIANCE $249 13 payments
  5. MOUNJARO $172 18 payments
  6. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $167 1 payment
  7. OFEV $164 6 payments
  8. BREZTRI $153 3 payments
  9. Dexcom G6 Transmitter $139 5 payments
  10. NURTEC ODT $131 7 payments
  11. Other $1,273 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

698

Median for Nurse Practitioner: 389

Drug cost

$6,365

Median for Nurse Practitioner: $21,885

Branded share of claims

21.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 74 $868
Doxycycline Hyclate Generic 54 $745
Fluticasone Propionate Generic 49 $676
Albuterol Sulfate Hfa Albuterol Sulfate Brand 33 $577
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 23 $461
Ciprofloxacin Hcl Generic 38 $359
Azithromycin Generic 85 $347
Omeprazole Generic 17 $299
Mupirocin Generic 28 $268
Cephalexin Generic 20 $237

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 1 billing codes

Paid by Medicare

$73

Medicare's payments for the services billed

Medicare patients

11

Average age 74

Services billed

11

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $108
$108 — —
JARDIANCE
  • Lilly USA, LLC $107
$107 — —
MOUNJARO
  • Lilly USA, LLC $97
$97 — —
QULIPTA
  • AbbVie, Inc. $96
$96 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $88
$88 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record